首頁 > 市場調查報告書 > 製藥

醫藥品原料藥

市場調查報告書

商品編碼

2048176

Carbamazepine市場 - 全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局，2021-2031年

Carbamazepine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球Carbamazepine市場預計將從 2025 年的 12.5 億美元成長到 2031 年的 18.2 億美元，複合年成長率為 6.46%。

Carbamazepine是一種廣泛使用的二苯並氮雜卓類抗驚厥藥物和情緒穩定劑，主要用於治療癲癇、三叉神經痛和雙相情感障礙。該市場的主要支撐源於治療慢性神經系統疾病的迫切臨床需求，以及該藥物作為一種經濟有效的一線非專利藥的既定地位。這些因素確保了整個醫療保健系統對卡馬西平的穩定需求，其特徵是持續穩定的消費，而不是短暫的市場波動或短期處方模式。然而，該市場在供應鏈可靠性和生產合規性方面面臨嚴峻挑戰。阻礙市場擴張的一個主要障礙是頻繁的產品短缺，這導致患者無法獲得必要的持續治療。例如，美國衛生系統藥劑師協會報告稱，截至2025年4月，已有270種活性成分供不應求，凸顯了確保Carbamazepine等重要且成熟的藥物穩定供應給依賴該藥物的患者群體這一持續存在的問題。

市場概覽
預測期	2027-2031
市場規模：2025年	12.5億美元
市場規模：2031年	18.2億美元
複合年成長率：2026-2031年	6.46%
成長最快的細分市場	糖尿病神經病變
最大的市場	亞太地區

市場促進因素

全球癲癇和癲癇發作性疾病盛行率的不斷上升是Carbamazepine市場的主要驅動力，患者需要長期堅持服用抗癲癇藥物。作為一線治療藥物，卡馬西平對於控制部分性發作和整體強直-陣攣性發作至關重要，儘管出現了更新的藥物，但其效用依然無可撼動。根據《柳葉刀神經病學》2024年3月報道，2021年全球約有34億人患有神經系統疾病，凸顯了該疾病的巨大負擔和需要治療的患者群體之廣。更具體地說，世界衛生組織（WHO）2024年2月報告稱，全球約有5000萬人患有癲癇，這使得Carbamazepine等用於預防嚴重癲癇復發的必需抗癲癇藥物的需求持續存在。推動市場消費成長的另一個因素是對經濟實惠的非專利藥的需求激增，這與旨在降低醫療成本並擴大患者覆蓋範圍的全球醫療保健舉措相契合。Carbamazepine是一種安全性已得到驗證的成熟藥物，與新型品牌抗癲癇藥物相比，由於其安全性高，因此受到公共醫療保險處方清單和保險公司的青睞，因為他們希望盡可能降低每位患者的治療成本。在主要藥品市場，這一趨勢尤其顯著，這些市場正積極推廣使用非專利以控制醫療預算。根據美國食品藥物管理局(FDA) 2024 年 2 月發布的報告，學名藥占美國所有處方箋的 91%，這反映出人們對價格合理的治療方案的偏好，直接惠及Carbamazepine等成熟的學名藥。因此，高臨床需求和經濟可行性相結合，確保了該藥物將繼續在全球神經系統疾病治療方案中佔據重要地位。

市場挑戰

全球Carbamazepine市場成長的主要障礙是持續的供應鏈不穩定以及由此導致的反覆產品短缺。這種不可靠性從根本上阻礙了市場擴張，因為它使製造商無法滿足治療癲癇和雙相情感障礙等慢性疾病所需的關鍵且持續的需求。當生產因合規性問題或原料短缺而中斷時，醫療機構往往被迫將患者轉用其他抗癲癇藥物以維持癲癇控制。這種非自願的轉換直接侵蝕了Carbamazepine的市場佔有率，並減少了持續的收入來源，因為處方醫生對該藥物的供應失去了信心。此外，這些物流故障給醫療保健行業帶來了嚴重的營運負擔，並限制了藥物的有效分銷。近期針對重要神經系統藥物的產業調查顯示，這種中斷的規模顯而易見。例如，歐盟製藥集團在2025年報告稱，所有28個參與國在2024年都面臨著向當地藥局供應藥品困難的問題。這種情況迫使藥劑師將大量資源用於應對庫存短缺，而不是專注於配藥，導致藥品消費量有限，並阻礙了市場保持穩定成長的能力，儘管該藥物在臨床上是必需的。

市場趨勢

正在從根本上改變市場格局的關鍵趨勢之一是向緩釋製劑的轉變。這是因為製藥公司優先考慮能夠確保藥物濃度穩定並提高患者依從性的製劑。傳統的速釋片劑容易出現藥物濃度波動，通常會加劇複視和協調障礙等副作用。因此，能夠將治療性血中濃度維持12至24小時的緩釋技術正逐漸成為臨床實務的首選。這些特殊製劑的商業性可行性在主要醫藥市場中已得到證實。例如，根據Express Pharma在2025年7月報道，截至2025年3月的12個月內，美國Carbamazepine緩釋片的市場規模達到7,100萬美元。此外，Carbamazepine在治療躁鬱症方面的應用不斷擴展，也成為成長要素的另一個重要因素，使其市場佔有率超越了傳統的抗癲癇藥物用途。Carbamazepine作為一種重要的情緒穩定劑，在治療急性躁症發作和維持治療中應用日益廣泛，尤其適用於對鋰鹽或其他第一線治療無效的患者。這一精神科適應症顯著擴大了潛在患者群體，並創造了新的收入來源，且該收入來源與癲癇的盛行率無關。根據世界衛生組織（世衛組織）2025年9月發布的關於雙相情感障礙的情況說明書，全球約有3700萬人患有這種慢性精神疾病，這是一個需要長期服藥的龐大群體。

The global carbamazepine market is projected to expand from USD 1.25 billion in 2025 to USD 1.82 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6.46%. Carbamazepine, a widely utilized dibenzazepine anticonvulsant and mood stabilizer, is primarily indicated for treating epilepsy, trigeminal neuralgia, and bipolar disorder. The market's foundational support stems from the critical clinical need to manage chronic neurological conditions and the drug's established status as a cost-effective, first-line generic therapy. These elements ensure consistent demand across healthcare systems, distinguishing the drug's steady consumption from transient market shifts or short-term prescribing patterns. However, the market faces considerable obstacles concerning supply chain dependability and manufacturing adherence. A significant challenge impeding expansion is the frequent occurrence of product shortages, which disrupts patient access to essential continuous therapy. For example, the American Society of Health-System Pharmacists reported 270 active drug shortages as of April 2025, highlighting an ongoing issue that complicates the consistent distribution of vital, established medications like carbamazepine to the patient populations who rely on them.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.25 Billion
Market Size 2031	USD 1.82 Billion
CAGR 2026-2031	6.46%
Fastest Growing Segment	Diabetic Neuropathy
Largest Market	Asia Pacific

Market Driver

The increasing global prevalence of epilepsy and seizure disorders serves as the fundamental catalyst for the carbamazepine market, necessitating long-term adherence to anticonvulsant therapies. As a first-line intervention, this medication remains critical for managing partial and generalized tonic-clonic seizures, reinforcing its utility despite the emergence of newer agents. The extensive burden of neurological diseases, affecting approximately 3.4 billion individuals globally in 2021, according to The Lancet Neurology in March 2024, underscores a vast patient population requiring intervention. More specifically, the World Health Organization reported in February 2024 that about 50 million people worldwide live with epilepsy, creating a continuous need for vital anticonvulsants like carbamazepine to prevent severe seizure recurrence. A parallel driver accelerating market consumption is the surge in demand for cost-effective generic formulations, aligning with global healthcare initiatives aimed at reducing expenditure while expanding patient coverage. Carbamazepine, an established molecule with a proven safety record, is favored by public health formularies and insurers seeking to minimize per-patient treatment costs compared to newer brand-name antiepileptics. This trend is particularly evident in key pharmaceutical markets where generic substitution is actively promoted to manage healthcare budgets. The Food and Drug Administration's February 2024 report indicated that generic drugs accounted for 91% of all prescriptions dispensed in the United States, reflecting a systemic prioritization of affordable therapeutics that directly benefits established generic agents such as carbamazepine. Thus, the combination of high clinical need and economic viability ensures the drug remains a staple in neurological care protocols globally.

Market Challenge

The primary obstacle to the growth of the Global Carbamazepine Market is the persistent instability of the supply chain and the resulting recurrence of product shortages. This unreliability fundamentally undermines market expansion by preventing manufacturers from meeting the critical, consistent demand required for treating chronic conditions such as epilepsy and bipolar disorder. When manufacturing compliance issues or raw material scarcities disrupt production, healthcare providers are often forced to transition patients to alternative anticonvulsants to maintain seizure control. This involuntary switching directly erodes carbamazepine's market share and reduces recurring revenue streams as prescribers lose confidence in the drug's availability. Furthermore, these logistical failures impose a severe operational burden on the healthcare sector, which limits the efficient distribution of the medication. The magnitude of this disruption is evident in recent industry findings concerning essential nervous system drugs; for instance, the Pharmaceutical Group of the European Union reported in 2025 that all 28 participating countries experienced difficulties in drug supply in community pharmacies throughout 2024. This situation forces pharmacists to divert significant resources to managing stockouts instead of focusing on dispensing therapy, thereby restricting consumption volume and hindering the market's ability to sustain steady growth despite the drug's critical clinical necessity.

Market Trends

A key trend fundamentally transforming the market is the shift towards extended-release dosage forms, as manufacturers prioritize formulations that ensure stable drug concentrations and enhance patient adherence. Conventional immediate-release tablets frequently lead to fluctuating drug levels, intensifying side effects such as double vision or poor coordination, which drives a clinical preference for modified-release technologies capable of sustaining therapeutic levels for 12 to 24 hours. The commercial viability of these specialized formulations is evident in major pharmaceutical economies; for example, Express Pharma reported in July 2025 that the U.S. market for carbamazepine extended-release tablets was valued at USD 71 million for the twelve months ending March 2025. Furthermore, the expanded therapeutic use of carbamazepine in managing bipolar disorder serves as a secondary growth driver, extending its market presence beyond its traditional antiepileptic application. Carbamazepine is increasingly utilized as an essential mood stabilizer for acute manic episodes and maintenance therapy, particularly for patients who do not respond to lithium or other primary treatments. This psychiatric indication significantly broadens the potential patient base, creating a separate revenue stream independent of epilepsy prevalence. The World Health Organization's September 2025 fact sheet on bipolar disorder estimated that approximately 37 million people globally live with this chronic mental health condition, representing a substantial demographic in need of long-term pharmacological intervention.

Key Market Players

Teva Pharmaceutical Industries Ltd.
Novartis AG
Mylan N.V.
Sun Pharmaceutical Industries Ltd.
Cipla Limited
Apotex Inc.
Aurobindo Pharma Ltd.
Zydus Cadila Ltd.
Torrent Pharmaceuticals Ltd.
Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Carbamazepine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbamazepine Market, By Sales Channel

Direct
Indirect

Carbamazepine Market, By End Use

Epilepsy
Trigeminal Neuralgia
Bipolar Disorder
Diabetic Neuropathy
Others

Carbamazepine Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbamazepine Market.

Available Customizations:

Global Carbamazepine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carbamazepine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Sales Channel (Direct, Indirect)
- 5.2.2. By End Use (Epilepsy, Trigeminal Neuralgia, Bipolar Disorder, Diabetic Neuropathy, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Carbamazepine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Sales Channel
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Carbamazepine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Sales Channel
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Carbamazepine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Sales Channel
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Carbamazepine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Sales Channel
    - 6.3.3.2.2. By End Use

7. Europe Carbamazepine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Sales Channel
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Carbamazepine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Sales Channel
    - 7.3.1.2.2. By End Use
- 7.3.2. France Carbamazepine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Sales Channel
    - 7.3.2.2.2. By End Use
- 7.3.3. United Kingdom Carbamazepine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Sales Channel
    - 7.3.3.2.2. By End Use
- 7.3.4. Italy Carbamazepine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Sales Channel
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Carbamazepine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Sales Channel
    - 7.3.5.2.2. By End Use

8. Asia Pacific Carbamazepine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Sales Channel
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Carbamazepine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Sales Channel
    - 8.3.1.2.2. By End Use
- 8.3.2. India Carbamazepine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Sales Channel
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Carbamazepine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Sales Channel
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Carbamazepine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Sales Channel
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Carbamazepine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Sales Channel
    - 8.3.5.2.2. By End Use

9. Middle East & Africa Carbamazepine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Sales Channel
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Carbamazepine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Sales Channel
    - 9.3.1.2.2. By End Use
- 9.3.2. UAE Carbamazepine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Sales Channel
    - 9.3.2.2.2. By End Use
- 9.3.3. South Africa Carbamazepine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Sales Channel
    - 9.3.3.2.2. By End Use

10. South America Carbamazepine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Sales Channel
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Carbamazepine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Sales Channel
    - 10.3.1.2.2. By End Use
- 10.3.2. Colombia Carbamazepine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Sales Channel
    - 10.3.2.2.2. By End Use
- 10.3.3. Argentina Carbamazepine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Sales Channel
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Carbamazepine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Teva Pharmaceutical Industries Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Mylan N.V.
15.4. Sun Pharmaceutical Industries Ltd.
15.5. Cipla Limited
15.6. Apotex Inc.
15.7. Aurobindo Pharma Ltd.
15.8. Zydus Cadila Ltd.
15.9. Torrent Pharmaceuticals Ltd.
15.10. Hikma Pharmaceuticals PLC